Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
Abstract Metastatic breast cancer (BC) is considered incurable, and it is generally treated with sequential single-agent therapies to control it with palliative intent. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are used in the front-line setting of hormone receptor (HR)-positive, HER2-negativ...
Main Authors: | Isabella O. Wender, Kayla Haines, Mohammad Jahanzeb |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-09-01
|
Series: | Oncology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40487-020-00126-0 |
Similar Items
-
Profile of palbociclib in the treatment of metastatic breast cancer
by: Ehab M, et al.
Published: (2016-05-01) -
Palbociclib in breast cancer neoadjuvant setting
by: Sílvia Alexandra Cabral Duarte, et al.
Published: (2021-08-01) -
Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01) -
Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
by: Masato Takahashi, et al.
Published: (2020-07-01) -
Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01)